

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT : Jackowski et al.

INVENTION: : MACROGLOBULIN BIOPOLYMER MARKERS
INDICATIVE OF INSULIN RESISTANCE

SERIAL NUMBER : 09/993,295

RECEIVED

FILING DATE : November 23, 2001

MAY 22 2003

EXAMINER: : (not assigned yet)

TECH CENTER 1600/2900

GROUP ART UNIT : 1741

ATTORNEY DOCKET NO. : 2132.099

TRANSMITTAL LETTER

CERTIFICATE UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being
deposited with the U.S. Postal Service as First Class mail
in an envelope addressed to Commissioner for Patents
P.O. Box 1450, Alexandria, VA 22313-1450 on 5-12-03

Susan Lander

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Please find enclosed for filing:

- Supplemental Information Disclosure Statement
- Certification Pursuant to 37 C.F.R. §1.97(e)
- Copy of International Search Report
- PTO-1449
- References

Respectfully submitted,


Date: 5/12/2003

By: Ferris H. Lander

Ferris H. Lander
Registration No. 43,377
McHale & Slavin, P.A.
4440 PGA Boulevard, Suite 402
Palm Beach Gardens, FL 33410
Telephone: (561) 625-6575

RECEIVED
MAY 19 2003
TC 1700

1741



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT : Jackowski et al.

INVENTION: : MACROGLOBULIN BIOPOLYMER MARKERS
INDICATIVE OF INSULIN RESISTANCE

SERIAL NUMBER : 09/993,295

RECEIVED

FILING DATE : November 23, 2001

MAY 22 2003

EXAMINER: : (not assigned yet)

TECH CENTER 1600/2900

GROUP ART UNIT : 1741

ATTORNEY DOCKET NO. : 2132.099

CERTIFICATION PURSUANT TO 37 C.F.R. §1.97 (e)

CERTIFICATE UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being
deposited with the U.S. Postal Service as First Class mail
in an envelope addressed to Commissioner for Patents
P.O. Box 1450, Alexandria, VA 22313-1450 on 5/12/03

Susan Lander

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. §1.97(e), Applicants hereby certify that each item of information contained in the accompanying Supplemental Information Disclosure Statement filed concurrently herewith was cited in a communication from a foreign patent office, namely an International Search Report for a counterpart European patent application, not more than three months prior to the filing of the accompanying Supplemental Information Disclosure Statement.

Accordingly, pursuant to 37 C.F.R. §1.97(e), Applicants request consideration and entry of the Supplemental Information Disclosure Statement.

Date: 5/12/2003

Respectfully Submitted,

Ferris H. Lander

Ferris H. Lander
Reg. No. 43,377
McHale & Slavin, P.A.
4440 PGA Boulevard, Suite 402
Palm Beach Gardens, FL 33410
Telephone: (561) 625-6575



RECEIVED
MAY 19 2003
TC 1700
X 12.9
RECEIVED CON't

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT : Jackowski et al.

INVENTION: : MACROGLOBULIN BIOPOLYMER MARKERS
INDICATIVE OF INSULIN RESISTANCE

SERIAL NUMBER : 09/993,295

RECEIVED CON't

FILING DATE : November 23, 2001

MAY 22 2003

EXAMINER: : (not assigned yet)

TECH CENTER 1600/2900

GROUP ART UNIT : 1741

ATTORNEY DOCKET NO. : 2132.099

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

CERTIFICATE UNDER 37 CFR 1.8(a)
I hereby certify that this correspondence is being
deposited with the U.S. Postal Service as First Class mail
in an envelope addressed to Commissioner for Patents
P.O. Box 1450, Alexandria, VA 22313-1450 on 5/12/03

Susan Lander

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the Duty to Disclose under 37 C.F.R. §1.56, the references cited on the accompanying form PTO-1449 are hereby brought to the attention of the Examiner for independent evaluation. A copy of each reference is enclosed. The references were cited in an International Search Report of the European Patent Office in the corresponding patent application.


A copy of the International Search Report is also enclosed, which satisfies the requirement for a concise statement of relevancy pursuant to M.P.E.P. §609 (1995).

Applicants submit that the present invention is patentable over these references.

Date: 5/12/2003

Respectfully Submitted,

Ferris H. Lander
Ferris H. Lander
Reg. No. 43,377
McHale & Slavin, P.A.
4440 PGA Boulevard, Suite 402
Palm Beach Gardens, FL 33410
Telephone: (561) 625-6575



RECEIVED
MAY 19 2003

Sheet 1 of 1

Form PTO-1449
(Rev. 2-88)

TC 1700

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
2132.099

APPLICATION NO.
09/993,295

APPLICANT
JACKOWSKI et al.

FILING DATE
11/23/01

GROUP
1741

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER'S INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,329,500	12/01	Webb et al.			RECEIVED
						MAY 22 2003
						TECH CENTER 1600/2900
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
X	WO 02/059604 ✓	08/02	PCT			X
X	WO 98/07036 ✓	02/98	PCT			X

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

X	✓		Van Cool, "α2-Macroglobulin Expression in Neuritic-Type Plaques in Patients With Alzheimer's Disease", Neurobiology of Aging (1993) Vol. 14, No. 3, pp. 233-237.				
			Ahmad, et al., "A Study of Plasma Alpha-2-Macroglobulin Levels in Type 2 Diabetic Subjects with Microalbuminuria", J. Assoc. Physicians of India (2001), Vol. 49, pp. 1062-1065.				
V	Y		Sesboue, et al., "Quantitative study of human blood alpha-1-antitrypsin, alpha-2-macroglobulin and inter-alpha-trypsin-inhibitor with respect to plasma renin activity", Clinica Chimica Acta (1983) Vol. 135, No. 1, pp. 23-34.				
			DATABASE EMBL"Online! Teich et al., "Alpha-2-macroglobulin (fragment)", retrieved from EMBL, Database accession no. Q9BQ22, XP-002237293.				

EXAMINER	DATE CONSIDERED

- EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.